Targets › MIR-23B
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Jul 2027.
Open in Phaseline: the race on MIR-23B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ARTHEx Biotech | ATX-01 miR-23b inhibitor (synthetic single-stranded oligonucleotide/anti-miR) | MIR-23B | Phase 1 | Myotonic Dystrophy 1 | Jul 2027 |
Myotonic Dystrophy 1 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.